News

Article

Study: Sore eyes a common symptom in COVID-19 patients

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.


In a study published by BMJ Open Ophthalmology, investigators sought to determine three objectives: whether ocular symptoms were different in chronic sufferers of anterior eye diseases; when the symptoms were experienced; and how long the symptoms lasted when compared to other COVID-19 patients.

Analysis
Results of an online questionnaire of self-reported data from 83 participants over the course of two months with confirmed diagnoses of COVID-19 sought to ascertain the type, frequency and duration of different disease symptoms.

Additionally, investigators compared anterior eye symptoms experienced by respondents before their diagnosis and during the COVID-19 state.

Results found the most reported symptoms to be dry eye (66%), fever (76%), fatigue (90%), and lose off smell/taste (70%).1

Further results found that participants reported a number of ocular symptoms indicative of viral conjunctivitis.

The most three common ocular symptoms included photophobia (18%), sores eyes (16%), and itchy eyes (17%). Of those, the presence of sore eyes was significantly higher in patients during their COVID-19 state (16%) versus their pre-COVID-19 state (5%).1


Data on these results of ocular symptoms before and during COVID-19 confirmed cases using the McNemar’s test for paired comparisons can be seen in Table 1.1


Participants also reported dry eye symptoms more frequently before (23%) rather than during their COVID-19 state (14%) — a change investigators found surprising. However, this was found to be lacking any statistical significance.

Similarly, symptoms reported by participants with an association to various types of conjunctivitis — including mucous discharge and gritty eyes linked to bacterial infection — did not have significant results.

Investigators found that 81% of participants reported experiencing ocular symptoms within two weeks of other COVID-19 symptoms, and 80% reported the symptoms lasting less than two weeks.

Despite conjunctivitis being linked as a potential indicator of COVID-19, the study’s investigators concluded that “conjunctivitis” — a broad term — should be used with caution when in association of the disease.

References

1. Pardhan S, Vaughan M, Zhang J, et al. Sore eyes as the most significant ocular symptom experienced by people with COVID-19: a comparison between pre-COVID-19 and during COVID-19 states. BMJ Open Ophthalmology 2020;5:e000632. doi: 10.1136/bmjophth-2020-000632

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
© 2025 MJH Life Sciences

All rights reserved.